[
  {
    "objectID": "advanced/index.html",
    "href": "advanced/index.html",
    "title": "Advanced Targeted Learning Methods",
    "section": "",
    "text": "Code\nlibrary(lmtp)\nset.seed(123)\ndata(example_data)\nfit &lt;- lmtp_tmle(example_data, trt = \"A\", outcome = \"Y\",\n                 baseline = c(\"L1\",\"L2\"),\n                 shift = function(data, trt) data[[trt]] + 0.5,\n                 folds = 2)\nsummary(fit)"
  },
  {
    "objectID": "workshop/index.html",
    "href": "workshop/index.html",
    "title": "Workshop: The Causal Roadmap and TMLE in Pharmacoepidemiology",
    "section": "",
    "text": "This workshop introduces the Causal Roadmap and Targeted Maximum Likelihood Estimation (TMLE) through a motivating example: a post-market evaluation of cardiovascular safety among patients treated with denosumab (Prolia) vs. zoledronic acid for osteoporosis. The goal is to show how causal inference frameworks help produce transparent, reproducible real-world evidence.\nIn 2023, Amgen conducted a large-scale retrospective cohort study across two US claims databases, comparing denosumab with zoledronic acid. After adjusting for confounding using inverse probability weighting, the study found no increased risk of myocardial infarction or stroke up to 36 months of follow-up【204†source】. Here, we will reconstruct a simplified version of this question using the causal roadmap and a TMLE implementation.\n\n\n\n\n\n\nNote\n\n\n\nGoal: Learn how to define, identify, and estimate a causal effect with TMLE, using machine learning for nuisance function estimation.\n\n\n Figure 1. The Causal Roadmap, adapted for pharmacoepidemiologic safety analysis."
  },
  {
    "objectID": "workshop/index.html#tmle-example",
    "href": "workshop/index.html#tmle-example",
    "title": "Introductory Workshop: The Causal Roadmap and TMLE",
    "section": "",
    "text": "Code\nlibrary(tmle)\n\n\nLoading required package: glmnet\n\n\nLoading required package: Matrix\n\n\nLoaded glmnet 4.1-8\n\n\nLoading required package: SuperLearner\n\n\nLoading required package: nnls\n\n\nLoading required package: gam\n\n\nLoading required package: splines\n\n\nLoading required package: foreach\n\n\nLoaded gam 1.22-5\n\n\nSuper Learner\n\n\nVersion: 2.0-29\n\n\nPackage created on 2024-02-06\n\n\nWelcome to the tmle package, version 2.0.1.1\n\nUse tmleNews() to see details on changes and bug fixes\n\n\nCode\nset.seed(1234)\nn &lt;- 500\nW &lt;- data.frame(age = rnorm(n, 60, 10), sex = rbinom(n, 1, 0.5))\nA &lt;- rbinom(n, 1, plogis(-1 + 0.02*W$age + 0.5*W$sex))\nY &lt;- rbinom(n, 1, plogis(-2 + 1*A + 0.03*W$age))\nres &lt;- tmle(Y = Y, A = A, W = W, family = \"binomial\")\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nLoading required namespace: dbarts\n\n\nError : Loading required package dbarts failed\n\n\nCode\nsummary(res)\n\n\n Initial estimation of Q\n     Procedure: cv-SuperLearner, ensemble\n     Model:\n         Y ~  SL.glm_All + tmle.SL.dbarts2_All + SL.glmnet_All\n\n     Coefficients: \n          SL.glm_All    1 \n     tmle.SL.dbarts2_All    0 \n       SL.glmnet_All    0 \n\n     Cross-validated pseudo R squared :  0.0707 \n\n Estimation of g (treatment mechanism)\n     Procedure: SuperLearner, ensemble\n     Model:\n         A ~  SL.glm_All + tmle.SL.dbarts.k.5_All + SL.gam_All \n\n     Coefficients: \n          SL.glm_All    1 \n     tmle.SL.dbarts.k.5_All    0 \n          SL.gam_All    0 \n\n Estimation of g.Z (intermediate variable assignment mechanism)\n     Procedure: No intermediate variable \n\n Estimation of g.Delta (missingness mechanism)\n     Procedure: No missingness, ensemble\n\n Bounds on g: (0.036, 1) \n\n Bounds on g for ATT/ATC: (0.036, 0.964) \n\n Marginal Mean under Treatment (EY1)\n   Parameter Estimate:  0.73099\n   Estimated Variance:  0.00066355\n              p-value:  &lt;2e-16\n    95% Conf Interval:  (0.6805, 0.78147)\n\n Marginal Mean under Comparator (EY0)\n   Parameter Estimate:  0.46608\n   Estimated Variance:  0.001368\n              p-value:  &lt;2e-16\n    95% Conf Interval:  (0.39358, 0.53857)\n\n Additive Effect\n   Parameter Estimate:  0.26491\n   Estimated Variance:  0.0020173\n              p-value:  3.676e-09\n    95% Conf Interval:  (0.17688, 0.35294)\n\n Additive Effect among the Treated\n   Parameter Estimate:  0.26824\n   Estimated Variance:  0.0021137\n              p-value:  5.3922e-09\n    95% Conf Interval:  (0.17813, 0.35835)\n\n Additive Effect among the Controls\n   Parameter Estimate:  0.26067\n   Estimated Variance:  0.0020284\n              p-value:  7.1302e-09\n    95% Conf Interval:  (0.1724, 0.34894)\n\n Relative Risk\n   Parameter  Estimate:  1.5684\n   Variance(log scale):  0.0074975\n               p-value:  2.0191e-07\n     95% Conf Interval:  (1.3236, 1.8585)\n\n Odds Ratio\n    Parameter  Estimate:  3.1129\n    Variance(log scale):  0.038959\n                p-value:  8.7655e-09\n      95% Conf Interval:  (2.1142, 4.5832)"
  },
  {
    "objectID": "estimands/index.html",
    "href": "estimands/index.html",
    "title": "An Introduction to Estimand Specification",
    "section": "",
    "text": "Attribute\nDescription\nExample\n\n\n\n\nPopulation\nWho is under study\nAdults with diabetes\n\n\nTreatment\nIntervention and comparator\nNew drug vs standard care\n\n\nOutcome\nTarget variable\n12-month mortality\n\n\nIntercurrent Events\nPost-randomization events\nTreatment switching\n\n\nSummary Measure\nContrast\nRisk difference (ATE)"
  },
  {
    "objectID": "bibliography/index.html",
    "href": "bibliography/index.html",
    "title": "Annotated Bibliography",
    "section": "",
    "text": "Topic\nCitation\nWhy It Matters\n\n\n\n\nCausal Roadmap\nDang et al. (2023) JCTS\nDefines framework for RWE."
  },
  {
    "objectID": "cases/index.html",
    "href": "cases/index.html",
    "title": "Causal roadmap tutorial applied to the case study of an AKI safety signal",
    "section": "",
    "text": "Welcome to the Causal Roadmap Tutorial.\nThis section walks through three major steps of the causal inference roadmap using an acute kidney injury (AKI) case study comparing sofosbuvir-containing vs non-sofosbuvir antiviral regimens.\nEach chapter corresponds to a key step of the causal roadmap:\n\nStep 1a – Causal Question and Causal Estimand\nDefining the causal question and selecting the estimand under the ICH E9(R1) framework.\nSteps 1b–2 – Causal Model and Observed Data\nBuilding the causal model, DAG, and mapping variables from the data-generating process.\nStep 3 – Identification and Causal Assumptions\nLinking the causal estimand to the observed data through identification assumptions.\n\n\n\n\nThese materials are designed to teach the first steps of the Causal Roadmap in a regulatory-grade RWE analysis.\nThe content aligns with the ICH E9(R1) estimand framework and follows a target trial emulation approach.\nBy the end of this section, you will be able to:\n\nDefine a causal question that aligns with clinical intent.\n\nIdentify estimands suitable for post-market safety evaluation.\n\nUnderstand how causal assumptions translate into statistical estimators."
  },
  {
    "objectID": "resources/index.html",
    "href": "resources/index.html",
    "title": "Resources",
    "section": "",
    "text": "(to do: add descriptions of each)\n\nBeyondTheATE.com\nTLverse handbook\nIntroduction to modern causal inference\nVisual guides to causal inference\n\n-https://vanderlaan-lab.org/"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Targeted Learning for Real-World Evidence",
    "section": "",
    "text": "Welcome!\nThis site introduces the Causal Roadmap, Targeted Maximum Likelihood Estimation (TMLE), and Super Learner for modern causal inference in epidemiology, with an emphasis on pharmacoepidemiology and clinical trial analysis.\n\n\nWarning: package 'ggplot2' was built under R version 4.4.3"
  },
  {
    "objectID": "workshop/index.html#why-tmle",
    "href": "workshop/index.html#why-tmle",
    "title": "Workshop: The Causal Roadmap and TMLE in Pharmacoepidemiology",
    "section": "4.1 Why TMLE?",
    "text": "4.1 Why TMLE?\nAs described by Katherine Hoffman in An Illustrated Guide to TMLE【202†source】【203†source】, TMLE: - Targets a specific estimand (e.g., ATE), rather than model coefficients. - Incorporates data-adaptive methods like Super Learner. - Provides valid standard errors and confidence intervals."
  },
  {
    "objectID": "workshop/index.html#why-super-learner",
    "href": "workshop/index.html#why-super-learner",
    "title": "Workshop: The Causal Roadmap and TMLE in Pharmacoepidemiology",
    "section": "4.2 Why Super Learner?",
    "text": "4.2 Why Super Learner?\nSuper Learner (SL) combines multiple algorithms (GLM, LASSO, random forests, etc.) through cross-validation to minimize prediction error. This ensemble approach ensures flexibility and robustness when estimating nuisance parameters.\n\n\nCode\nlibrary(SuperLearner)\n\n\nLoading required package: nnls\n\n\nLoading required package: gam\n\n\nLoading required package: splines\n\n\nLoading required package: foreach\n\n\nLoaded gam 1.22-5\n\n\nSuper Learner\n\n\nVersion: 2.0-29\n\n\nPackage created on 2024-02-06\n\n\nCode\nset.seed(123)\nsl_libs &lt;- c('SL.glm', 'SL.glmnet', 'SL.ranger', 'SL.earth')"
  },
  {
    "objectID": "workshop/03-tmle.html",
    "href": "workshop/03-tmle.html",
    "title": "3. TMLE Concepts and Implementation",
    "section": "",
    "text": "Why TMLE?\nTMLE provides a robust, efficient estimator for causal effects combining outcome regression and propensity score modeling.\nIt is doubly robust and allows the use of machine learning while preserving valid inference.\n\n\nCode\nlibrary(tmle)\n\n\nLoading required package: glmnet\n\n\nLoading required package: Matrix\n\n\nLoaded glmnet 4.1-8\n\n\nLoading required package: SuperLearner\n\n\nLoading required package: nnls\n\n\nLoading required package: gam\n\n\nLoading required package: splines\n\n\nLoading required package: foreach\n\n\nLoaded gam 1.22-5\n\n\nSuper Learner\n\n\nVersion: 2.0-29\n\n\nPackage created on 2024-02-06\n\n\nWelcome to the tmle package, version 2.0.1.1\n\nUse tmleNews() to see details on changes and bug fixes\n\n\nCode\nlibrary(SuperLearner)\nset.seed(123)\nfit &lt;- tmle(Y, A, W, family = \"binomial\",\n            Q.SL.library = c(\"SL.glm\", \"SL.glmnet\", \"SL.ranger\"),\n            g.SL.library = c(\"SL.glm\", \"SL.ranger\"))\n\n\nLoading required namespace: ranger\n\n\nCode\nsummary(fit)\n\n\n Initial estimation of Q\n     Procedure: cv-SuperLearner, ensemble\n     Model:\n         Y ~  SL.glm_All + SL.glmnet_All + SL.ranger_All\n\n     Coefficients: \n          SL.glm_All    1 \n       SL.glmnet_All    0 \n       SL.ranger_All    0 \n\n     Cross-validated pseudo R squared :  0.0489 \n\n Estimation of g (treatment mechanism)\n     Procedure: SuperLearner, ensemble\n     Model:\n         A ~  SL.glm_All + SL.ranger_All \n\n     Coefficients: \n          SL.glm_All    1 \n       SL.ranger_All    0 \n\n Estimation of g.Z (intermediate variable assignment mechanism)\n     Procedure: No intermediate variable \n\n Estimation of g.Delta (missingness mechanism)\n     Procedure: No missingness, ensemble\n\n Bounds on g: (0.0229, 1) \n\n Bounds on g for ATT/ATC: (0.0229, 0.9771) \n\n Marginal Mean under Treatment (EY1)\n   Parameter Estimate:  0.8545\n   Estimated Variance:  0.00021034\n              p-value:  &lt;2e-16\n    95% Conf Interval:  (0.82607, 0.88292)\n\n Marginal Mean under Comparator (EY0)\n   Parameter Estimate:  0.7213\n   Estimated Variance:  0.00049874\n              p-value:  &lt;2e-16\n    95% Conf Interval:  (0.67753, 0.76508)\n\n Additive Effect\n   Parameter Estimate:  0.1332\n   Estimated Variance:  0.00070162\n              p-value:  4.9435e-07\n    95% Conf Interval:  (0.081279, 0.18511)\n\n Additive Effect among the Treated\n   Parameter Estimate:  0.12591\n   Estimated Variance:  0.00069858\n              p-value:  1.9004e-06\n    95% Conf Interval:  (0.074105, 0.17771)\n\n Additive Effect among the Controls\n   Parameter Estimate:  0.14433\n   Estimated Variance:  0.0007439\n              p-value:  1.2115e-07\n    95% Conf Interval:  (0.090873, 0.19779)\n\n Relative Risk\n   Parameter  Estimate:  1.1847\n   Variance(log scale):  0.0012346\n               p-value:  1.4158e-06\n     95% Conf Interval:  (1.1058, 1.2691)\n\n Odds Ratio\n    Parameter  Estimate:  2.2691\n    Variance(log scale):  0.02565\n                p-value:  3.1176e-07\n      95% Conf Interval:  (1.6578, 3.1059)\n\n\n Figure 3. TMLE step-by-step schematic."
  },
  {
    "objectID": "workshop/04-superlearner.html",
    "href": "workshop/04-superlearner.html",
    "title": "4. SuperLearner and Ensemble Methods",
    "section": "",
    "text": "The Idea Behind Super Learner\nSuper Learner combines multiple models into one optimal prediction algorithm using cross-validation.\n\n\nCode\nlibrary(SuperLearner)\n\n\nLoading required package: nnls\n\n\nLoading required package: gam\n\n\nLoading required package: splines\n\n\nLoading required package: foreach\n\n\nLoaded gam 1.22-5\n\n\nSuper Learner\n\n\nVersion: 2.0-29\n\n\nPackage created on 2024-02-06\n\n\nCode\nset.seed(123)\n#sl_lib &lt;- c(\"SL.glm\", \"SL.mean\", \"SL.glmnet\", \"SL.randomForest\")\nsl_lib &lt;- c(\"SL.glm\") #simpler library for speed\nSL_fit &lt;- SuperLearner(Y, X = W, newX = W, family = binomial(), SL.library = sl_lib)\nsummary(SL_fit)\n\n\n                  Length Class  Mode       \ncall                 6   -none- call       \nlibraryNames         1   -none- character  \nSL.library           2   -none- list       \nSL.predict        1000   -none- numeric    \ncoef                 1   -none- numeric    \nlibrary.predict   1000   -none- numeric    \nZ                 1000   -none- numeric    \ncvRisk               1   -none- numeric    \nfamily              13   family list       \nfitLibrary           1   -none- list       \ncvFitLibrary         0   -none- NULL       \nvarNames             2   -none- character  \nvalidRows           10   -none- list       \nmethod               3   -none- list       \nwhichScreen          2   -none- logical    \ncontrol              3   -none- list       \ncvControl            4   -none- list       \nerrorsInCVLibrary    1   -none- logical    \nerrorsInLibrary      1   -none- logical    \nmetaOptimizer        8   nnls   list       \nenv                  9   -none- environment\ntimes                3   -none- list       \n\n\n Figure 4. Ensemble learning in Super Learner."
  },
  {
    "objectID": "workshop/05-integrated-analysis.html",
    "href": "workshop/05-integrated-analysis.html",
    "title": "5. Putting It All Together",
    "section": "",
    "text": "Integrating the Steps\nIn this final section, we bring together all steps of the Causal Roadmap and Targeted Learning pipeline.\n\n\nCode\n# Full workflow\n\n\n Figure 5. Integrating the Causal Roadmap and Targeted Learning for real-world evidence."
  },
  {
    "objectID": "cases/index.html#about-this-tutorial",
    "href": "cases/index.html#about-this-tutorial",
    "title": "Causal roadmap tutorial applied to the case study of an AKI safety signal",
    "section": "",
    "text": "These materials are designed to teach the first steps of the Causal Roadmap in a regulatory-grade RWE analysis.\nThe content aligns with the ICH E9(R1) estimand framework and follows a target trial emulation approach.\nBy the end of this section, you will be able to:\n\nDefine a causal question that aligns with clinical intent.\n\nIdentify estimands suitable for post-market safety evaluation.\n\nUnderstand how causal assumptions translate into statistical estimators."
  },
  {
    "objectID": "cases/step2_causal_model.html",
    "href": "cases/step2_causal_model.html",
    "title": "Steps 1b–2 – Causal Model and Observed Data",
    "section": "",
    "text": "The causal model specifies assumptions and relationships among variables needed for valid inference.\n\n\nWe emulate a two‑arm pragmatic trial:\n\nA=1: Sofosbuvir‑containing regimen\n\nA=0: Non‑sofosbuvir regimen\n\nFollow‑up: 90 days for first AKI or censoring\n\n\n\n\nW ─▶ A ─▶ Y\n│     │\n└────▶ Y\n\nW: Baseline confounders (age, CKD, cirrhosis, HIV)\nA: Treatment assignment\nY: AKI outcome within 90 days\n\n\n\n\nExchangeability: No unmeasured confounding given W\n\nPositivity: All W values have non‑zero probability of receiving each treatment\n\nConsistency: Each individual’s outcome under observed A equals counterfactual Yᵃ"
  },
  {
    "objectID": "cases/step2_causal_model.html#targettrial-emulation",
    "href": "cases/step2_causal_model.html#targettrial-emulation",
    "title": "Steps 1b–2 – Causal Model and Observed Data",
    "section": "",
    "text": "We emulate a two‑arm pragmatic trial:\n\nA=1: Sofosbuvir‑containing regimen\n\nA=0: Non‑sofosbuvir regimen\n\nFollow‑up: 90 days for first AKI or censoring"
  },
  {
    "objectID": "cases/step2_causal_model.html#simplified-dag",
    "href": "cases/step2_causal_model.html#simplified-dag",
    "title": "Steps 1b–2 – Causal Model and Observed Data",
    "section": "",
    "text": "W ─▶ A ─▶ Y\n│     │\n└────▶ Y\n\nW: Baseline confounders (age, CKD, cirrhosis, HIV)\nA: Treatment assignment\nY: AKI outcome within 90 days\n\n\n\n\nExchangeability: No unmeasured confounding given W\n\nPositivity: All W values have non‑zero probability of receiving each treatment\n\nConsistency: Each individual’s outcome under observed A equals counterfactual Yᵃ"
  },
  {
    "objectID": "cases/step2_causal_model.html#observed-data-vector",
    "href": "cases/step2_causal_model.html#observed-data-vector",
    "title": "Steps 1b–2 – Causal Model and Observed Data",
    "section": "Observed Data Vector",
    "text": "Observed Data Vector\n[ O = (W, A, T, ) ]\n\n\n\nVariable\nDescription\n\n\n\n\nW\nBaseline covariates (demographics, comorbidities)\n\n\nA\nBinary treatment: SOF=1, non‑SOF=0\n\n\nT\nFollow‑up time to AKI or censoring\n\n\nΔ\nIndicator: 1=AKI, 0=censored\n\n\n\n\nCensoring Rules\n\n\n\nDataset\nPurpose\nCensoring\n\n\n\n\nPrimary\nHypothetical no‑switch\nAKI, administrative, or switch\n\n\nSensitivity\nTreatment‑policy (ITT)\nAKI or admin only\n\n\n\nThese data definitions ensure reproducibility and map directly to the causal model."
  }
]